Title |
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
|
---|---|
Published in |
Breast Cancer Research and Treatment, January 2019
|
DOI | 10.1007/s10549-018-05100-z |
Pubmed ID | |
Authors |
Alberto Ocana, Marta Gil-Martin, Silvia Antolín, María Atienza, Álvaro Montaño, Nuria Ribelles, Ander Urruticoechea, Alejandro Falcón, Sonia Pernas, Javier Orlando, Juan Carlos Montero, Maria José Escudero, Sara Benito, Rosalía Caballero, Eva Carrasco, Federico Rojo, Atanasio Pandiella, Manuel Ruiz-Borrego |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 50% |
Japan | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 65 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 17% |
Researcher | 10 | 15% |
Student > Master | 7 | 11% |
Other | 5 | 8% |
Student > Postgraduate | 4 | 6% |
Other | 14 | 22% |
Unknown | 14 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 20% |
Biochemistry, Genetics and Molecular Biology | 12 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 14% |
Agricultural and Biological Sciences | 2 | 3% |
Immunology and Microbiology | 2 | 3% |
Other | 9 | 14% |
Unknown | 18 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2019.
All research outputs
#14,150,857
of 23,122,481 outputs
Outputs from Breast Cancer Research and Treatment
#3,051
of 4,689 outputs
Outputs of similar age
#229,082
of 438,184 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#44
of 69 outputs
Altmetric has tracked 23,122,481 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,689 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,184 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.